ID   SRBP1_HUMAN             Reviewed;        1147 AA.
AC   P36956; B0I4X3; B0I4X4; D3DXC4; Q16062; Q59F52; Q6P4R7; Q6PFW7;
AC   Q6PJ36; Q8TAK9;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   05-FEB-2008, sequence version 2.
DT   10-MAY-2017, entry version 183.
DE   RecName: Full=Sterol regulatory element-binding protein 1;
DE            Short=SREBP-1;
DE   AltName: Full=Class D basic helix-loop-helix protein 1;
DE            Short=bHLHd1;
DE   AltName: Full=Sterol regulatory element-binding transcription factor 1;
DE   Contains:
DE     RecName: Full=Processed sterol regulatory element-binding protein 1;
GN   Name=SREBF1; Synonyms=BHLHD1, SREBP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SREBP-1A), NUCLEOTIDE SEQUENCE
RP   [MRNA] OF 1-29 (ISOFORM SREBP-1C), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   1035-1147 (ISOFORMS SREBP-1B AND SREBP-1C), PARTIAL PROTEIN SEQUENCE,
RP   AND VARIANT ALA-1000.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=8402897; DOI=10.1016/S0092-8674(05)80095-9;
RA   Yokoyama C., Wang X., Briggs M.R., Admon A., Wu J., Hua X.,
RA   Goldstein J.L., Brown M.S.;
RT   "SREBP-1, a basic-helix-loop-helix-leucine zipper protein that
RT   controls transcription of the low density lipoprotein receptor gene.";
RL   Cell 75:187-197(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-1000.
RC   TISSUE=Fetal brain;
RX   PubMed=7759101; DOI=10.1016/0888-7543(95)80009-B;
RA   Hua X., Wu J., Goldstein J.L., Brown M.S., Hobbs H.H.;
RT   "Structure of the human gene encoding sterol regulatory element
RT   binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to
RT   chromosomes 17p11.2 and 22q13.";
RL   Genomics 25:667-673(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS SREBP-1ADELTA AND SREBP-1CDELTA),
RP   AND SUBCELLULAR LOCATION (ISOFORMS SREBP-1ADELTA AND SREBP-1CDELTA).
RC   TISSUE=Liver;
RX   PubMed=18267114; DOI=10.1016/j.bbrc.2008.02.004;
RA   Harada N., Yonemoto H., Yoshida M., Yamamoto H., Yin Y., Miyamoto A.,
RA   Hattori A., Wu Q., Nakagawa T., Nakano M., Teshigawara K.,
RA   Mawatari K., Hosaka T., Takahashi A., Nakaya Y.;
RT   "Alternative splicing produces a constitutively active form of human
RT   SREBP-1.";
RL   Biochem. Biophys. Res. Commun. 368:820-826(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORM SREBP-1A).
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS SREBP-1A AND 4), AND
RP   VARIANTS SER-306 AND LEU-834.
RC   TISSUE=Brain, Placenta, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 31-1147 (ISOFORM
RP   SREBP-1A/4).
RC   TISSUE=Spleen;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   CHARACTERIZATION, AND MUTAGENESIS.
RX   PubMed=8626610; DOI=10.1074/jbc.271.17.10379;
RA   Hua X., Sakai J., Brown M.S., Goldstein J.L.;
RT   "Regulated cleavage of sterol regulatory element binding proteins
RT   requires sequences on both sides of the endoplasmic reticulum
RT   membrane.";
RL   J. Biol. Chem. 271:10379-10384(1996).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-117, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1060, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 319-394.
RX   PubMed=9634703; DOI=10.1016/S0969-2126(98)00067-7;
RA   Parraga A., Bellsolell L., Ferre-D'Amare A.R., Burley S.K.;
RT   "Co-crystal structure of sterol regulatory element binding protein 1a
RT   at 2.3-A resolution.";
RL   Structure 6:661-672(1998).
CC   -!- FUNCTION: Transcriptional activator required for lipid
CC       homeostasis. Regulates transcription of the LDL receptor gene as
CC       well as the fatty acid and to a lesser degree the cholesterol
CC       synthesis pathway (By similarity). Binds to the sterol regulatory
CC       element 1 (SRE-1) (5'-ATCACCCCAC-3'). Has dual sequence
CC       specificity binding to both an E-box motif (5'-ATCACGTGA-3') and
CC       to SRE-1 (5'-ATCACCCCAC-3'). {ECO:0000250|UniProtKB:Q9WTN3}.
CC   -!- SUBUNIT: Forms a tight complex with SCAP in the ER membrane.
CC       Efficient DNA binding of the soluble transcription factor fragment
CC       requires dimerization with another bHLH protein. Interacts with
CC       LMNA. Interacts with CEBPA, the interaction produces a
CC       transcriptional synergy (By similarity).
CC       {ECO:0000250|UniProtKB:Q9WTN3}.
CC   -!- INTERACTION:
CC       P45481:Crebbp (xeno); NbExp=2; IntAct=EBI-948328, EBI-296306;
CC       Q96RN5:MED15; NbExp=6; IntAct=EBI-948328, EBI-394506;
CC       Q96EB6:SIRT1; NbExp=2; IntAct=EBI-948338, EBI-1802965;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:Q9WTN3}; Multi-pass membrane protein
CC       {ECO:0000255}. Golgi apparatus membrane
CC       {ECO:0000250|UniProtKB:Q9WTN3}; Multi-pass membrane protein
CC       {ECO:0000255}. Cytoplasmic vesicle, COPII-coated vesicle membrane
CC       {ECO:0000250|UniProtKB:Q9WTN3}; Multi-pass membrane protein
CC       {ECO:0000255}. Note=Moves from the endoplasmic reticulum to the
CC       Golgi in the absence of sterols. {ECO:0000250|UniProtKB:Q9WTN3}.
CC   -!- SUBCELLULAR LOCATION: Processed sterol regulatory element-binding
CC       protein 1: Nucleus {ECO:0000250|UniProtKB:Q9WTN3}.
CC   -!- SUBCELLULAR LOCATION: Isoform SREBP-1aDelta: Nucleus
CC       {ECO:0000269|PubMed:18267114}.
CC   -!- SUBCELLULAR LOCATION: Isoform SREBP-1cDelta: Nucleus
CC       {ECO:0000269|PubMed:18267114}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=SREBP-1A;
CC         IsoId=P36956-1; Sequence=Displayed;
CC       Name=SREBP-1B;
CC         IsoId=P36956-2; Sequence=VSP_002150;
CC       Name=SREBP-1C;
CC         IsoId=P36956-3; Sequence=VSP_002149, VSP_002150;
CC         Note=Predominantly expressed in liver and adipose tissues.;
CC       Name=4;
CC         IsoId=P36956-4; Sequence=VSP_030859;
CC         Note=No experimental confirmation available.;
CC       Name=SREBP-1aDelta;
CC         IsoId=P36956-5; Sequence=VSP_047598, VSP_047599;
CC         Note=The absence of Golgi proteolytic processing requirement
CC         makes this isoform constitutively active in transactivation of
CC         lipogenic gene promoters.;
CC       Name=SREBP-1cDelta;
CC         IsoId=P36956-6; Sequence=VSP_002149, VSP_047598, VSP_047599;
CC         Note=The absence of Golgi proteolytic processing requirement
CC         makes this isoform constitutively active in transactivation of
CC         lipogenic gene promoters.;
CC   -!- TISSUE SPECIFICITY: Expressed in a wide variety of tissues, most
CC       abundant in liver and adrenal gland. In fetal tissues lung and
CC       liver shows highest expression. Isoform SREBP-1C predominates in
CC       liver, adrenal gland and ovary, whereas isoform SREBP-1A
CC       predominates in hepatoma cell lines. Isoform SREBP-1A and isoform
CC       SREBP-1C are found in kidney, brain, white fat, and muscle.
CC   -!- PTM: At low cholesterol the SCAP/SREBP complex is recruited into
CC       COPII vesicles for export from the ER. In the Golgi complex SREBPs
CC       are cleaved sequentially by site-1 and site-2 protease. The first
CC       cleavage by site-1 protease occurs within the luminal loop, the
CC       second cleavage by site-2 protease occurs within the first
CC       transmembrane domain and releases the transcription factor from
CC       the Golgi membrane. Apoptosis triggers cleavage by the cysteine
CC       proteases caspase-3 and caspase-7.
CC   -!- PTM: Phosphorylated by AMPK, leading to suppress protein
CC       processing and nuclear translocation, and repress target gene
CC       expression. Phosphorylation at Ser-402 by SIK1 represses activity
CC       possibly by inhibiting DNA-binding (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the SREBP family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB28522.2; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAD92846.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Sterol regulatory element-
CC       binding protein entry;
CC       URL="https://en.wikipedia.org/wiki/Sterol_regulatory_element_binding_protein";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U00968; AAC50051.2; -; mRNA.
DR   EMBL; S66167; AAB28522.2; ALT_INIT; mRNA.
DR   EMBL; S66168; AAB28523.1; -; mRNA.
DR   EMBL; AB373958; BAG06742.1; -; mRNA.
DR   EMBL; AB373959; BAG06743.1; -; mRNA.
DR   EMBL; AC122129; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471196; EAW55689.1; -; Genomic_DNA.
DR   EMBL; CH471196; EAW55690.1; -; Genomic_DNA.
DR   EMBL; BC023621; AAH23621.1; -; mRNA.
DR   EMBL; BC026962; AAH26962.1; -; mRNA.
DR   EMBL; BC057388; AAH57388.1; -; mRNA.
DR   EMBL; BC063281; AAH63281.1; -; mRNA.
DR   EMBL; AB209609; BAD92846.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS11189.1; -. [P36956-1]
DR   CCDS; CCDS32583.1; -. [P36956-4]
DR   PIR; A48845; A48845.
DR   RefSeq; NP_001005291.1; NM_001005291.2. [P36956-4]
DR   RefSeq; NP_004167.3; NM_004176.4. [P36956-1]
DR   UniGene; Hs.592123; -.
DR   UniGene; Hs.733635; -.
DR   PDB; 1AM9; X-ray; 2.30 A; A/B/C/D=319-400.
DR   PDBsum; 1AM9; -.
DR   ProteinModelPortal; P36956; -.
DR   SMR; P36956; -.
DR   BioGrid; 112598; 60.
DR   DIP; DIP-331N; -.
DR   IntAct; P36956; 16.
DR   MINT; MINT-2803077; -.
DR   STRING; 9606.ENSP00000348069; -.
DR   iPTMnet; P36956; -.
DR   PhosphoSitePlus; P36956; -.
DR   BioMuta; SREBF1; -.
DR   DMDM; 166897633; -.
DR   MaxQB; P36956; -.
DR   PaxDb; P36956; -.
DR   PeptideAtlas; P36956; -.
DR   PRIDE; P36956; -.
DR   Ensembl; ENST00000261646; ENSP00000261646; ENSG00000072310. [P36956-1]
DR   Ensembl; ENST00000355815; ENSP00000348069; ENSG00000072310. [P36956-4]
DR   GeneID; 6720; -.
DR   KEGG; hsa:6720; -.
DR   UCSC; uc002grt.3; human. [P36956-1]
DR   CTD; 6720; -.
DR   DisGeNET; 6720; -.
DR   GeneCards; SREBF1; -.
DR   HGNC; HGNC:11289; SREBF1.
DR   HPA; CAB005406; -.
DR   HPA; HPA043343; -.
DR   HPA; HPA043878; -.
DR   MIM; 184756; gene.
DR   neXtProt; NX_P36956; -.
DR   OpenTargets; ENSG00000072310; -.
DR   PharmGKB; PA335; -.
DR   eggNOG; KOG2588; Eukaryota.
DR   eggNOG; ENOG410XSVP; LUCA.
DR   GeneTree; ENSGT00390000017651; -.
DR   HOGENOM; HOG000007091; -.
DR   HOVERGEN; HBG061592; -.
DR   InParanoid; P36956; -.
DR   KO; K07197; -.
DR   OMA; GKYTGGH; -.
DR   OrthoDB; EOG091G01RE; -.
DR   PhylomeDB; P36956; -.
DR   TreeFam; TF313894; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1655829; Regulation of cholesterol biosynthesis by SREBP (SREBF).
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   SignaLink; P36956; -.
DR   SIGNOR; P36956; -.
DR   ChiTaRS; SREBF1; human.
DR   EvolutionaryTrace; P36956; -.
DR   GeneWiki; SREBF1; -.
DR   GenomeRNAi; 6720; -.
DR   PMAP-CutDB; P36956; -.
DR   PRO; PR:P36956; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000072310; -.
DR   CleanEx; HS_SREBF1; -.
DR   ExpressionAtlas; P36956; baseline and differential.
DR   Genevisible; P36956; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005635; C:nuclear envelope; TAS:ProtInc.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0032403; F:protein complex binding; IEA:Ensembl.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0004879; F:RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0032810; F:sterol response element binding; IDA:HGNC.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IDA:HGNC.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0071398; P:cellular response to fatty acid; IEA:Ensembl.
DR   GO; GO:0009267; P:cellular response to starvation; ISS:HGNC.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0007623; P:circadian rhythm; TAS:Reactome.
DR   GO; GO:0045444; P:fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0008610; P:lipid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:ProtInc.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0042789; P:mRNA transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045542; P:positive regulation of cholesterol biosynthetic process; IEA:Ensembl.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0010867; P:positive regulation of triglyceride biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0019217; P:regulation of fatty acid metabolic process; IEA:Ensembl.
DR   GO; GO:0003062; P:regulation of heart rate by chemical signal; IEA:Ensembl.
DR   GO; GO:1903146; P:regulation of mitophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1903214; P:regulation of protein targeting to mitochondrion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   GO; GO:0051591; P:response to cAMP; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032094; P:response to food; IEA:Ensembl.
DR   GO; GO:0033762; P:response to glucagon; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0032570; P:response to progesterone; IEA:Ensembl.
DR   GO; GO:0032526; P:response to retinoic acid; IEA:Ensembl.
DR   CDD; cd00083; HLH; 1.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   Pfam; PF00010; HLH; 1.
DR   SMART; SM00353; HLH; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   PROSITE; PS50888; BHLH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Cholesterol metabolism;
KW   Complete proteome; Cytoplasmic vesicle; Direct protein sequencing;
KW   DNA-binding; Endoplasmic reticulum; Golgi apparatus; Lipid metabolism;
KW   Membrane; Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   Steroid metabolism; Sterol metabolism; Transcription;
KW   Transcription regulation; Transmembrane; Transmembrane helix.
FT   CHAIN         1   1147       Sterol regulatory element-binding protein
FT                                1.
FT                                /FTId=PRO_0000127447.
FT   CHAIN         1    490       Processed sterol regulatory element-
FT                                binding protein 1.
FT                                /FTId=PRO_0000314029.
FT   TOPO_DOM      1    487       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    488    508       Helical. {ECO:0000255}.
FT   TOPO_DOM    509    547       Lumenal. {ECO:0000255}.
FT   TRANSMEM    548    568       Helical. {ECO:0000255}.
FT   TOPO_DOM    569   1147       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      323    373       bHLH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00981}.
FT   REGION        1     60       Transcriptional activation (acidic).
FT   REGION      234    497       Interaction with LMNA. {ECO:0000250}.
FT   REGION      373    394       Leucine-zipper.
FT   COMPBIAS     61    178       Pro/Ser-rich.
FT   COMPBIAS    427    462       Gly/Pro/Ser-rich.
FT   SITE        460    461       Cleavage; by caspase-3 and caspase-7.
FT                                {ECO:0000250}.
FT   SITE        490    491       Cleavage; by S2P. {ECO:0000250}.
FT   SITE        530    531       Cleavage; by S1P. {ECO:0000305}.
FT   MOD_RES      98     98       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P56720}.
FT   MOD_RES     117    117       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     337    337       Phosphoserine; by SIK1. {ECO:0000250}.
FT   MOD_RES     338    338       Phosphoserine; by SIK1. {ECO:0000250}.
FT   MOD_RES     396    396       Phosphoserine; by AMPK. {ECO:0000250}.
FT   MOD_RES     402    402       Phosphoserine; by SIK1. {ECO:0000250}.
FT   MOD_RES     457    457       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9WTN3}.
FT   MOD_RES    1060   1060       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1     29       MDEPPFSEAALEQALGEPCDLDAALLTDI -> MDCTF
FT                                (in isoform SREBP-1C and isoform SREBP-
FT                                1cDelta). {ECO:0000303|PubMed:18267114,
FT                                ECO:0000303|PubMed:8402897}.
FT                                /FTId=VSP_002149.
FT   VAR_SEQ      30     30       E -> EGEVGAGRGRANGLDAPRAGADRGAMDCTFE (in
FT                                isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_030859.
FT   VAR_SEQ     469    470       AK -> TE (in isoform SREBP-1aDelta and
FT                                isoform SREBP-1cDelta).
FT                                {ECO:0000303|PubMed:18267114}.
FT                                /FTId=VSP_047598.
FT   VAR_SEQ     471   1147       Missing (in isoform SREBP-1aDelta and
FT                                isoform SREBP-1cDelta).
FT                                {ECO:0000303|PubMed:18267114}.
FT                                /FTId=VSP_047599.
FT   VAR_SEQ    1035   1147       VFLHEATARLMAGASPTRTHQLLDRSLRRRAGPGGKGGAVA
FT                                ELEPRPTRREHAEALLLASCYLPPGFLSAPGQRVGMLAEAA
FT                                RTLEKLGDRRLLHDCQQMLMRLGGGTTVTSS -> LMDVLT
FT                                SESAWALPQHLGKGFPSPSGHKVPGWHGRMD (in
FT                                isoform SREBP-1B and isoform SREBP-1C).
FT                                {ECO:0000303|PubMed:8402897}.
FT                                /FTId=VSP_002150.
FT   VARIANT     306    306       N -> S (in dbSNP:rs17855793).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_038468.
FT   VARIANT     309    309       A -> T (in dbSNP:rs35188700).
FT                                /FTId=VAR_038469.
FT   VARIANT     417    417       V -> M (in dbSNP:rs2229590).
FT                                /FTId=VAR_038470.
FT   VARIANT     580    580       V -> M (in dbSNP:rs36215896).
FT                                /FTId=VAR_038471.
FT   VARIANT     746    746       R -> H (in dbSNP:rs2228461).
FT                                /FTId=VAR_038472.
FT   VARIANT     834    834       S -> L (in dbSNP:rs17855792).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_038473.
FT   VARIANT    1000   1000       T -> A (in dbSNP:rs1042017).
FT                                {ECO:0000269|PubMed:7759101,
FT                                ECO:0000269|PubMed:8402897}.
FT                                /FTId=VAR_038474.
FT   VARIANT    1008   1008       A -> P (in dbSNP:rs35014224).
FT                                /FTId=VAR_038475.
FT   MUTAGEN     455    455       S->A: No effect on proteolytic
FT                                processing. {ECO:0000269|PubMed:8626610}.
FT   MUTAGEN     456    456       D->A: No effect on proteolytic
FT                                processing. {ECO:0000269|PubMed:8626610}.
FT   MUTAGEN     457    457       S->A: No effect on proteolytic
FT                                processing. {ECO:0000269|PubMed:8626610}.
FT   MUTAGEN     460    460       D->A: No effect on proteolytic
FT                                processing. {ECO:0000269|PubMed:8626610}.
FT   MUTAGEN     466    466       D->A: No effect on proteolytic
FT                                processing. {ECO:0000269|PubMed:8626610}.
FT   MUTAGEN     481    481       G->A: No effect on proteolytic
FT                                processing. {ECO:0000269|PubMed:8626610}.
FT   MUTAGEN     482    482       M->A: No effect on proteolytic
FT                                processing. {ECO:0000269|PubMed:8626610}.
FT   MUTAGEN     483    483       L->A: No effect on proteolytic
FT                                processing. {ECO:0000269|PubMed:8626610}.
FT   MUTAGEN     484    487       DRSR->AS: Strong reduction of proteolytic
FT                                processing in response to low sterol.
FT                                {ECO:0000269|PubMed:8626610}.
FT   MUTAGEN     484    484       D->A: Loss of proteolytic processing in
FT                                response to low sterol.
FT                                {ECO:0000269|PubMed:8626610}.
FT   MUTAGEN     485    485       R->A: No effect on proteolytic
FT                                processing. {ECO:0000269|PubMed:8626610}.
FT   MUTAGEN     527    527       R->A: Loss of proteolytic processing in
FT                                response to low sterol.
FT                                {ECO:0000269|PubMed:8626610}.
FT   HELIX       321    350       {ECO:0000244|PDB:1AM9}.
FT   HELIX       359    396       {ECO:0000244|PDB:1AM9}.
SQ   SEQUENCE   1147 AA;  121675 MW;  58F28870739FF259 CRC64;
     MDEPPFSEAA LEQALGEPCD LDAALLTDIE DMLQLINNQD SDFPGLFDPP YAGSGAGGTD
     PASPDTSSPG SLSPPPATLS SSLEAFLSGP QAAPSPLSPP QPAPTPLKMY PSMPAFSPGP
     GIKEESVPLS ILQTPTPQPL PGALLPQSFP APAPPQFSST PVLGYPSPPG GFSTGSPPGN
     TQQPLPGLPL ASPPGVPPVS LHTQVQSVVP QQLLTVTAAP TAAPVTTTVT SQIQQVPVLL
     QPHFIKADSL LLTAMKTDGA TVKAAGLSPL VSGTTVQTGP LPTLVSGGTI LATVPLVVDA
     EKLPINRLAA GSKAPASAQS RGEKRTAHNA IEKRYRSSIN DKIIELKDLV VGTEAKLNKS
     AVLRKAIDYI RFLQHSNQKL KQENLSLRTA VHKSKSLKDL VSACGSGGNT DVLMEGVKTE
     VEDTLTPPPS DAGSPFQSSP LSLGSRGSGS GGSGSDSEPD SPVFEDSKAK PEQRPSLHSR
     GMLDRSRLAL CTLVFLCLSC NPLASLLGAR GLPSPSDTTS VYHSPGRNVL GTESRDGPGW
     AQWLLPPVVW LLNGLLVLVS LVLLFVYGEP VTRPHSGPAV YFWRHRKQAD LDLARGDFAQ
     AAQQLWLALR ALGRPLPTSH LDLACSLLWN LIRHLLQRLW VGRWLAGRAG GLQQDCALRV
     DASASARDAA LVYHKLHQLH TMGKHTGGHL TATNLALSAL NLAECAGDAV SVATLAEIYV
     AAALRVKTSL PRALHFLTRF FLSSARQACL AQSGSVPPAM QWLCHPVGHR FFVDGDWSVL
     STPWESLYSL AGNPVDPLAQ VTQLFREHLL ERALNCVTQP NPSPGSADGD KEFSDALGYL
     QLLNSCSDAA GAPAYSFSIS SSMATTTGVD PVAKWWASLT AVVIHWLRRD EEAAERLCPL
     VEHLPRVLQE SERPLPRAAL HSFKAARALL GCAKAESGPA SLTICEKASG YLQDSLATTP
     ASSSIDKAVQ LFLCDLLLVV RTSLWRQQQP PAPAPAAQGT SSRPQASALE LRGFQRDLSS
     LRRLAQSFRP AMRRVFLHEA TARLMAGASP TRTHQLLDRS LRRRAGPGGK GGAVAELEPR
     PTRREHAEAL LLASCYLPPG FLSAPGQRVG MLAEAARTLE KLGDRRLLHD CQQMLMRLGG
     GTTVTSS
//
